4.8/5 on Trustpilot with 50k+ reviews!

Metacam Chewable Tablets for Dogs

Metacam Chewable Tablets for Dogs

Images are for illustration purposes only. Packaging may change from time to time and images on our website may or may not be updated.

  • 1mg » Priced per Tablet £0.49
  • 2.5mg » Priced per Tablet £0.79

Selection of 2 products from

£0.49 to £0.79

Description

Metacam is one of the most widely used and safe treatments for osteoarthritis, or degenerative joint disease, in dogs and cats. The chewable tablets are just for dogs and are intended as an alternative to the liquid suspension which is also available. Metacam can also be used to treat other conditions where an anti-0inflammatory and pain-relieving effect is required. These include injuries affecting the bones or joints as well as surgical operations. A dose is given once daily. The starting dose can be at twice the dose rate as the continuing medication and this is often given by injection. Metacam can be used for both acute and chronic conditions.

Presentation

Chewable tablets, which are round mottled beige biconvex tablet, scored on the upper side with embedded code either "M10" or "M25" on one side. The tablet can be divided into equal halves.

Uses

Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs.

For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

Dosage and administration

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day, which can be given orally or alternatively using Metacam 5 mg/ml solution for injection. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam body weight. Each chewable contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively. Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal. Metacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

Body Weight (kg)

No. of Chewable Tablets

No. of Chewable Tablets

mg/kg

1 mg

2.5 mg

4.0 - 7.0

½

0.13 - 0.1

7.1 - 10.0

1

0.14 - 0.1

10.1 - 15.0

0.15 - 0.1

15.1 - 20.0

2

0.13 - 0.1

20.1 - 25.0

1

0.12 - 0.1

25.1 - 35.0

0.15 - 0.1

35.1 - 50.0

2

0.14 - 0.1

The use of Metacam Oral Suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Metacam Oral Suspension is recommended.

A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Contra-indications, warnings, etc

Do not use in pregnant or lactating animals.

Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml oral suspension for cats should be used.

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, letharthy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

In case of overdose, symptomatic treatment should be initiated.

User precautions

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the Doctor.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

For animal treatment only.

Keep out of reach and sight of children.

Pharmaceutical precautions

Store in the original package in order to protect from light.

This veterinary medicinal product does not require any special storage conditions.

Legal category

POM-V

Packaging Quantities

Metacam chewable tablets are supplied in:

Cardboard boxes containing 7, 84 or 252 tablets in Alu/Alu child-resistant blisters.

Not all pack sizes may be marketed.

Further information

Pharmacodynamic properties

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Pharmacokinetic particulars

Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.

Marketing Authorisation Holder (if different from distributor)

Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim am Rhein

Germany

Marketing authorisation number

Metacam 1 mg chewable tablets for dogs.

EU/2/97/004/043 7 tablets.

EU/2/97/004/044 84 tablets.

EU/2/97/004/045 252 tablets.

Metacam 2.5 mg chewable tablets for dogs.

EU/2/97/004/046 7 tablets.

EU/2/97/004/047 84 tablets.

EU/2/97/004/048 252 tablets.

GTIN (Global Trade Item No)

Metacam 1 mg Chewable Tablets for Dogs - 84 tablets

5012917010329

Metacam 2.5 mg Chewable Tablets for Dogs - 84 tablets

5012917010336

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

1mg » Priced per Tablet

Metacam 1 mg chewable tablets for dogs, Metacam 2.5 mg chewable tablets for dogs

Presentation

Round mottled beige biconvex chewable tablets, scored on the upper side with embedded code either "M10" or "M25" on one side. The tablet can be divided into equal halves. One chewable tablet contains: Active substance: meloxicam 1 mg or meloxicam 2.5 mg.

Uses

For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Dosage and administration

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day, which can be given orally or alternatively using Metacam 5 mg/ml solution for injection for dogs and cats.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.

Each chewable tablet can be halved for accurate dosing according to the individual body weight of the dog. Metacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

The use of Metacam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Metacam oral suspension for dogs is recommended.

A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Contra-indications, warnings, etc

Do not use in pregnant or lactating animals.

Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml oral suspension for cats should be used.

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the

following convention:

• very common (more than 1 in 10 animals treated displaying adverse reactions)

• common (more than 1 but less than 10 animals in 100 animals treated)

• uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

• rare (more than 1 but less than 10 animals in 10,000 animals treated)

• very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

In case of overdose, symptomatic treatment should be initiated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Keep out of the sight and reach of children. For animal treatment only.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Cardboard boxes containing 7, 84 or 252 tablets in Alu/Alu child-resistant blisters. Not all pack sizes may be marketed.

Further information

Pharmacodynamic properties

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Pharmacokinetic particulars

Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated in faeces and the remainder in urine.

Marketing Authorisation Holder (if different from distributor)

Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim am Rhein

Germany

Marketing Authorisation Number

Metacam 1 mg chewable tablets for dogs

EU/2/97/004/043 7 tablets

EU/2/97/004/044 84 tablets

EU/2/97/004/045 252 tablets

Metacam 2.5 mg chewable tablets for dogs

EU/2/97/004/046 7 tablets

EU/2/97/004/047 84 tablets

EU/2/97/004/048 252 tablets

2.5mg » Priced per Tablet

Metacam 1 mg chewable tablets for dogs, Metacam 2.5 mg chewable tablets for dogs

Presentation

Round mottled beige biconvex chewable tablets, scored on the upper side with embedded code either "M10" or "M25" on one side. The tablet can be divided into equal halves. One chewable tablet contains: Active substance: meloxicam 1 mg or meloxicam 2.5 mg.

Uses

For alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Dosage and administration

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day, which can be given orally or alternatively using Metacam 5 mg/ml solution for injection for dogs and cats.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.

Each chewable tablet can be halved for accurate dosing according to the individual body weight of the dog. Metacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

The use of Metacam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Metacam oral suspension for dogs is recommended.

A clinical response is usually seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Contra-indications, warnings, etc

Do not use in pregnant or lactating animals.

Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Metacam 0.5 mg/ml oral suspension for cats should be used.

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the

following convention:

• very common (more than 1 in 10 animals treated displaying adverse reactions)

• common (more than 1 but less than 10 animals in 100 animals treated)

• uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

• rare (more than 1 but less than 10 animals in 10,000 animals treated)

• very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

In case of overdose, symptomatic treatment should be initiated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Keep out of the sight and reach of children. For animal treatment only.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Cardboard boxes containing 7, 84 or 252 tablets in Alu/Alu child-resistant blisters. Not all pack sizes may be marketed.

Further information

Pharmacodynamic properties

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Pharmacokinetic particulars

Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated in faeces and the remainder in urine.

Marketing Authorisation Holder (if different from distributor)

Boehringer Ingelheim Vetmedica GmbH

55216 Ingelheim am Rhein

Germany

Marketing Authorisation Number

Metacam 1 mg chewable tablets for dogs

EU/2/97/004/043 7 tablets

EU/2/97/004/044 84 tablets

EU/2/97/004/045 252 tablets

Metacam 2.5 mg chewable tablets for dogs

EU/2/97/004/046 7 tablets

EU/2/97/004/047 84 tablets

EU/2/97/004/048 252 tablets

Delivery Information

Reviews (5)

Summary of Reviews for Metacam Chewable Tablets for Dogs

Overall 5
Effectiveness
Ease Of Use
Value For Money
Absence Of Side Effects
5 out of 5 (100%) customers would recommend this product.
5 stars (3 reviews)
4 stars (2 reviews)
3 stars (0 reviews)
2 stars (0 reviews)
1 stars (0 reviews)

Only verified purchasers of this product can leave a review.

45 Metacam chewable
Verified Purchase

By Jayne Deering on 30 August 2019

Easy to split in two, and tasty.

Customer recommends this product

45 Good product which my dog has to have long term
Verified Purchase

By Breda Ellis on 15 July 2017

My dog has been on Metacam for at least four years now and they certainly help her. Buying from Viovet was quite a lot cheaper that from my former source. Easy to order and efficient, speedy delivery.

Customer recommends this product

55 Good painkiller
Verified Purchase

By Mike Robinson on 10 August 2015

very helpful for the dog.

Customer recommends this product

55 Metacam For Arthritis
Verified Purchase

By Harry Holland on 11 February 2015

Our 10 year old + Golden Retriever has like many dogs developed arthritis with the passing years. One knee joint in particular would play up and she would become lame from time to time. She has been on fish oil capsules and Glucosamine tablets, like us, for some while. The addition of one quarter Metacam tablet per day has worked wonders. She is back to playing around like a puppy - but not for so long off course. Just lovely to see her so happy.

Customer recommends this product

1 person found this review helpful

55 Really helps the pain
Verified Purchase

By Peter Mcanearney on 1 December 2014

Metacam has proved that it really does help our 70kg Rhodesian Ridgeback. We recommend the product to anyone whose dog has lost his 'sparkle' owing to the pain of arthritis.

Customer recommends this product

2 people found this review helpful

Q & A

Below are some recent questions we've received regarding Metacam Chewable Tablets for Dogs, including answers from our team.

1 April 2017 at 6:02pm

How much

Sian

How many tablets would a 20kg shih tzu need per day?

  • Veterinary Advisor

A 20kg dog would need 2 of the 1mg tablets once daily.

10 October 2015 at 2:03am

How many tablets do I require?

Phyllis Henderson

  • VioVet customer since 2015
  • From: East Dunbartonshire, United Kingdom

I have 14 year old Labrador who is starting to slow down, he has been on rate of 35 metacalm per day which he has recently been refusing to take this is liquid form. If I could change this to tablet form how many do I require to buy? Thank you. X

  • Non-Executive Director

If your dog weighs 35 kg and has been on the 35 kg dose of the liquid, then the correct dose would be 2 tablets per day. (This applies for dogs up to 50 kg in fact.) Your vet would have to advise on this though.